Zaina P. Qureshi
YOU?
Author Swipe
View article: Investigating the link between helicobacter pylori infection and idiopathic thrombocytopenic purpura a case-control study
Investigating the link between helicobacter pylori infection and idiopathic thrombocytopenic purpura a case-control study Open
Background: Immune thrombocytopenic purpura (ITP) is an autoimmune disorder marked by isolated thrombocytopenia. Recent studies suggest a link between Helicobacter pylori (H. pylori) infection and ITP, possibly through molecular mimicry an…
View article: Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States
Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States Open
Patients with MM with 1 to 3 prior LOTs experienced high economic burden largely attributable to MM-related treatment, highlighting the need for more cost-effective therapies.
View article: Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma
Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma Open
Introduction: Ciltacabtagene autoleucel (cilta-cel) is an established effective treatment strategy for relapsed/refractory multiple myeloma in fifth line or later (5L+) and was recently approved for patients who have received ≥1 prior line…
View article: Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs
Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs Open
Aim: Bruton’s tyrosine kinase inhibitors (BTKis), including ibrutinib and acalabrutinib, transformed the treatment landscape of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) by improving outcomes compared with che…
View article: Venous Thromboembolism in Dermatological, Pulmonary, and Cardiac Disorders: A Systematic Review of Emergency Presentations and Interdisciplinary Management Strategies
Venous Thromboembolism in Dermatological, Pulmonary, and Cardiac Disorders: A Systematic Review of Emergency Presentations and Interdisciplinary Management Strategies Open
View article: Prevalence and Risk Factors of Hepatocellular Carcinoma in Patients Co-infected With Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV): A Cross-Sectional Retrospective Study
Prevalence and Risk Factors of Hepatocellular Carcinoma in Patients Co-infected With Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV): A Cross-Sectional Retrospective Study Open
View article: A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases Open
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphom…
View article: Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database
Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database Open
View article: Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database
Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database Open
View article: Incremental medical cost of delirium in elderly patients with cognitive impairment: analysis of a nationwide administrative database in Japan
Incremental medical cost of delirium in elderly patients with cognitive impairment: analysis of a nationwide administrative database in Japan Open
Objectives Delirium is a neuropsychiatric disorder that commonly occurs in elderly patients with cognitive impairment. The economic burden of delirium in Japan has not been well characterised. In this study, we assessed incremental medical…
View article: Demographic and clinical characteristics of patients with delirium: analysis of a nationwide Japanese medical database
Demographic and clinical characteristics of patients with delirium: analysis of a nationwide Japanese medical database Open
Objectives Delirium commonly occurs during hospitalisation and is associated with increased mortality, especially in elderly patients. This study aimed to determine the demographic and clinical characteristics of patients with delirium in …
View article: POS0947 LONG-TERM GOLIMUMAB PERSISTENCE: 5-YEAR TREATMENT RETENTION DATA POOLED FROM FIVE PHASE III CLINICAL TRIALS IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
POS0947 LONG-TERM GOLIMUMAB PERSISTENCE: 5-YEAR TREATMENT RETENTION DATA POOLED FROM FIVE PHASE III CLINICAL TRIALS IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS Open
View article: 0446 Trends and Patterns in Prescriptions of Hypnotics for The Treatment of Insomnia in Japan: Analysis of A Nationwide Japanese Claims Database
0446 Trends and Patterns in Prescriptions of Hypnotics for The Treatment of Insomnia in Japan: Analysis of A Nationwide Japanese Claims Database Open
Introduction Optimal treatment of insomnia is uncommon, given the lack of awareness regarding insomnia management. While the treatment landscape for insomnia has evolved following the introduction of orexin receptor antagonists (ORA), few …
View article: Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes
Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes Open
Despite switching drugs, some schizophrenia patients continue to have high levels of disease burden, suggesting that currently available therapies are insufficiently effective in these patients.
View article: Correction to: Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study
Correction to: Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study Open
View article: A Feasibility Study: Testing Whether a Sleep Application Providing Objective Sleep Data to Physicians Improves Patient–Physician Communication Regarding Sleep Experiences, Habits, and Behaviors
A Feasibility Study: Testing Whether a Sleep Application Providing Objective Sleep Data to Physicians Improves Patient–Physician Communication Regarding Sleep Experiences, Habits, and Behaviors Open
SleepLife® and its related physician portal can facilitate physician-patient communication, and it captures patient sleep outcomes including behaviors and habits. Patients were highly engaged with the program, while physicians d…
View article: Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer’s Disease: A Structured Literature Review
Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer’s Disease: A Structured Literature Review Open
Background: Sleep disturbances are frequent in Alzheimer’s disease (AD). Objective: To summarize the impact of sleep disturbances on AD patients and their caregivers and the effects of currently available sleep therapies. Methods: Publishe…
View article: DOP71 Low occurrence of colectomy with long-term (up to 4 years) golimumab treatment in patients with moderate-to-severe active Ulcerative Colitis: Data from the PURSUIT maintenance and long-term extension studies
DOP71 Low occurrence of colectomy with long-term (up to 4 years) golimumab treatment in patients with moderate-to-severe active Ulcerative Colitis: Data from the PURSUIT maintenance and long-term extension studies Open
Background In a previous real-world study of long-term (up to 4 years) treatment with golimumab (GLM) in ulcerative colitis (UC), patients reported a low overall colectomy incidence (5.8%).1 This analysis evaluates the incidence of colecto…
View article: Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study
Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study Open
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The…
View article: Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant Open
Article full textThe above graphical abstract represents a summary of the manuscript. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed …
View article: Incremental Healthcare Utilization and Cost Burden of Comorbid Insomnia in Alzheimer’s Disease Patients
Incremental Healthcare Utilization and Cost Burden of Comorbid Insomnia in Alzheimer’s Disease Patients Open
Background: Insomnia is associated with worsened clinical outcomes among Alzheimer’s disease dementia (AD) patients, increased caregiver burden, and healthcare utilization. Objective: This study aimed to characterize the incremental health…
View article: PND49 An Assessment of Real-World Healthcare Provider Experiences with Insomnia Medications Focusing on Suvorexant in the United States (US)
PND49 An Assessment of Real-World Healthcare Provider Experiences with Insomnia Medications Focusing on Suvorexant in the United States (US) Open
View article: 316 Comorbidities among medically diagnosed insomnia patients: A MarketScan database study
316 Comorbidities among medically diagnosed insomnia patients: A MarketScan database study Open
Introduction A large proportion of patients with insomnia frequently suffer from comorbid medical conditions. Literature on the relationship between insomnia and associated comorbidities is severely limited due to challenges of generalizab…
View article: 378 Use of a Clinician’s Global Impression of Severity scale to measure insomnia severity in Alzheimer’s disease-dementia patients
378 Use of a Clinician’s Global Impression of Severity scale to measure insomnia severity in Alzheimer’s disease-dementia patients Open
Introduction Full montage polysomnography (PSG) is the gold standard for the objective evaluation of sleep but is time consuming and inaccessible to most clinicians. A Clinician’s Global Impression of Severity (CGI-S) scale can be used in …
View article: 354 Trends in the Drug-Sparing Effects for Benzodiazepines and Prescription Opioids among Insomnia Patients on Suvorexant in the US
354 Trends in the Drug-Sparing Effects for Benzodiazepines and Prescription Opioids among Insomnia Patients on Suvorexant in the US Open
Introduction Use of benzodiazepines to treat insomnia has been associated with serious side effects and abuse potential. Insomnia patients are at high risk of opioid abuse and better sleep patterns may help to reduce opioid use. This study…
View article: PMH6 Association of Atypical Treatment Switches with Outcomes in Patients with Schizophrenia
PMH6 Association of Atypical Treatment Switches with Outcomes in Patients with Schizophrenia Open
View article: Assessment of Real-Life Outcomes in Schizophrenia Patients according to Compliance
Assessment of Real-Life Outcomes in Schizophrenia Patients according to Compliance Open
Objective . To describe and compare demographics, outcomes and comorbidities in schizophrenia patients by treatment compliance. Methods . This was a cross-sectional survey of hospital- or office-based psychiatrists who saw ≥6 schizophrenia…
View article: A flexible, computationally efficient method for fitting the proportional hazards model to interval-censored data: A Novel Method for Fitting the Proportional Hazards Model to Interval-Censored Data
A flexible, computationally efficient method for fitting the proportional hazards model to interval-censored data: A Novel Method for Fitting the Proportional Hazards Model to Interval-Censored Data Open
The proportional hazards model (PH) is currently the most popular regression model for analyzing time-to-event data. Despite its popularity, the analysis of interval-censored data under the PH model can be challenging using many available …
View article: PMH63 A REAL WORLD ASSESSMENT OF OUTCOMES IN SCHIZOPHRENIA PATIENTS ACCORDING TO TREATMENT RESPONSE
PMH63 A REAL WORLD ASSESSMENT OF OUTCOMES IN SCHIZOPHRENIA PATIENTS ACCORDING TO TREATMENT RESPONSE Open
View article: PMH65 ASSESSMENT OF OUTCOMES AND SYMPTOM SEVERITY IN SCHIZOPHRENIA PATIENTS ACCORDING TO PHYSICIAN PERCEPTION OF ILLNESS
PMH65 ASSESSMENT OF OUTCOMES AND SYMPTOM SEVERITY IN SCHIZOPHRENIA PATIENTS ACCORDING TO PHYSICIAN PERCEPTION OF ILLNESS Open